Elevance Health Inc. (ELV) Stock: Price, Forecast & Analyst Target
Elevance Health Inc. (ELV) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $390.16 (-2.66%), as of the Nov 19, 2026 trading session; market cap $84.3B. Expected results Jan 27, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Elevance Health Inc. · ELV · NYSE · Healthcare · Medical - Healthcare Plans
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Elevance Health (ELV)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth, at a cheap price, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Jan 27, 2027
- Altman Z 3.07 · Piotroski F 7
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $390.16 | |
| Change on the day | -2.66% | |
| 52-week range | $274.84–$450.69 | |
| Market capitalisation | $84.3B | — |
| Price / earnings (trailing) | 18.48 | |
| Shares traded on the day | 2.73M | |
| Beta (volatility vs the S&P 500) | 0.71 |
Why Elevance Health scores 88
Share price, last 12 months +41.4%
$303.78 $429.65
What the price assumes
2.6% a year of free-cash-flow growth for ten years is what a $92.83B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $6.51B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 7.1% either way.
- +1.7%Jan ’24
- +4.4%Apr ’24
- -8.8%Jul ’24
- -13.3%Oct ’24
- +2.6%Jan ’25
- +5.0%Apr ’25
- -19.6%Jul ’25
- -2.5%Oct ’25
- +7.5%Jan ’26
- +5.5%Apr ’26
- -12.6%Jul ’26
- +1.2%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +1.2% | -5.9% | |
| Beat | Beat | -12.6% | -8.8% | |
| Beat | Beat | +5.5% | +14.8% | |
| Beat | Miss | +7.5% | +5.5% | |
| Beat | Beat | -2.5% | -4.1% | |
| In line | Beat | -19.6% | -18.6% | |
| Beat | Beat | +5.0% | +1.7% | |
| Beat | Beat | +2.6% | +2.2% | |
| Miss | Beat | -13.3% | -15.7% | |
| Beat | Beat | -8.8% | -7.4% | |
| Beat | In line | +4.4% | +6.0% | |
| Beat | Beat | +1.7% | +4.5% |
Beats have usually been rewarded — 7 of 10 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “rate actions”, “greater operating”, “recent rate”, “share growth” — none of them came up in Q2 FY2026.
- Getting louder: “margin improvement” (2 → 7 mentions), “selling season” (2 → 7 mentions), “health benefits” (2 → 5 mentions).
- Gone quiet: “broadly aligned”, “provider connectivity”, “outpatient surgery”, “sustainable performance” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 86 to 88 while the share price moved -3.1% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 71% of 38 rate it a buy; the average target sits +19.6% from the price of $390.16.
- Last 90 days: 10 rating actions, every one a reaffirmation.
- Our signals: Exceptional band; strongest pillar Growth Durability (88), weakest Financial Safety (45).
Here we and the crowd agree.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Elevance Health (ELV): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Elevance Health (ELV), and what does it report?
Short answer
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. Elevance Health Inc. (ELV) is listed on NYSE. Healthcare / Medical Healthcare Plans SEC filing business address: Indianapolis, IN. It employs 96,615 people and is led by Gail Koziara Boudreaux. The market values it at $84.3B.
What do the latest results show for Elevance Health (ELV)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $50.44B Oct 21, 2026
- Latest report · revenue estimate
- $49.28B Oct 21, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 21, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 21, 2026 | $50.44B | $49.28B | $6.9900 | $4.7100 |
| Jul 15, 2026 | $49.83B | $48.88B | $7.4500 | $6.2100 |
| Apr 22, 2026 | $49.49B | $48.20B | $12.5800 | $10.8200 |
| Jan 28, 2026 | $49.31B | $49.84B | $3.3300 | $3.1000 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $50.71B | $1.19B | $5.32 (diluted) |
| Q4 FY2025 | $49.75B | $547M | $2.47 (diluted) |
| Q1 FY2026 | $50.18B | $1.76B | $8.00 (diluted) |
| Q2 FY2026 | $50.47B | $1.46B | $6.71 (diluted) |
What are the financial strengths and risks for Elevance Health (ELV)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 3.07 · Piotroski F 7. Trailing ratios: ROE 11.5% · ROA 4.0% · current ratio 1.47.
What should you watch next at Elevance Health (ELV)?
Short answer · as of
The next earnings report is expected on Jan 27, 2027. Current published price targets run low $395.00 · high $523.00 · consensus $470.11 · median $478.50 against a quoted price of $390.16 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Elevance Health compare with its peers?
Short answer
Elevance Health's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $26.17 Nov 19, 2026 | $8.13B | 97 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $3.77 Nov 19, 2026 | $2.02B | 94 5-pillar Nov 18, 2026 | |
| $65.62 Nov 19, 2026 | $32.5B | 91 5-pillar Nov 18, 2026 | |
| Elevance Health (ELV) — this page | $390.16 | $84.3B | 88 |
| $341.25 Nov 19, 2026 | $65.1B | 86 5-pillar Nov 18, 2026 | |
| $80.06 Nov 19, 2026 | $102B | 81 5-pillar Nov 18, 2026 | |
| $380.00 Nov 19, 2026 | $45.6B | 79 5-pillar Nov 18, 2026 | |
| $273.09 Nov 19, 2026 | $72.0B | 78 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $349.91 Nov 18, 2026 | $314B | 76 5-pillar Nov 18, 2026 | |
| $6.72 Nov 18, 2026 | $1.41B | 73 5-pillar Nov 18, 2026 | |
| $203.34 Nov 19, 2026 | $10.6B | 68 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $395.00 – $523.00
- Consensus target
- $470.11
- Median target
- $478.50
Consensus record · Captured .
Measured against a quoted price of $390.16 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 24
- Identified insiders
- 8
- Purchases
- 3
- Sales
- 16
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ELV in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Baupost Group | Seth Klarman | Q3 2026 | 9.83% | $495.81M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Elevance Health (ELV)?
What Investors Ask About Elevance Health (ELV) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the ELV research dossier (written May 10, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ELV?
ELV carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ELV a good stock to buy?
Stock Expert AI does not rate ELV buy, sell or hold. Elevance Health Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ELV stock price today?
The last price recorded for Elevance Health Inc. (ELV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ELV price target?
The analyst consensus price target for Elevance Health Inc. (ELV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about ELV stock?
Analysts generally view Elevance Health favorably, citing its strong market position, diversified service offerings, and growth potential. Key valuation metrics such as P/E ratio and dividend yield suggest a reasonable valuation relative to earnings and a steady income stream for investors. Analysts also highlight the company's focus on digital health and value-based care as positive drivers for future growth.
What are the key factors to evaluate for ELV?
Elevance Health Inc. (ELV) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does ELV data refresh on this page?
ELV's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ELV's recent stock price performance?
Elevance Health Inc. (ELV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 46 figures on this page — 1 from SEC filings and earnings calls, 38 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold ELV
Funds in our ETF coverage that list ELV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| IHF ETF | 9.29% |
